Administration of intravitreal triamcinolone for exudative macular degeneration

P. L. Penfold, J. F. Gyory, A. B. Hunyor, F. A. Billson

Research output: Contribution to journalArticlepeer-review


Purpose. To investigate the efficacy of intravitreal triamcinolone in patients with subfoveal and juxtafoveal exudative macular lesions considered unsuitable for laser photocoagulation. Methods. Data were collated from 30 eyes of 28 patients who had been treated with ir travitreal injection of triamcinolone (4mg). The subsequent visual acuity (VA) of treated eyes was compared with published VA outcomes of untreated eyes with a similar condition. Patients were classified into 3 types according to their response to reatment. Results. Within 2 weeks of treatment exudation decreased and vision improved in the majority of patients (87% - Types I & II), this trend continuing in longer term follow-up. The overall VA outcome for teated eyes was significantly better than published VA data for untreated exudative macular lesions. No serious side effects of a single injection of triamcinolone have been detected in patients followed for up to 2 years. Conclusions. The preliminary findings are encouraging, however, presently the treatment would ideally be administered in the context of a prospective, case-controlled clinical trial.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Issue number3
Publication statusPublished - 15 Feb 1996

Fingerprint Dive into the research topics of 'Administration of intravitreal triamcinolone for exudative macular degeneration'. Together they form a unique fingerprint.

Cite this